TABLE 4.
TCMR | AMR | ||
---|---|---|---|
Pathway term name | Adjusted P | Pathway term name | Adjusted P |
CTLA4 signaling in cytotoxic T lymphocytes (96) | 1.9 × 10−7 | Natural killer cell signaling | 3.6 × 10−6 |
T cell receptor signaling (109) | 1.9 × 10−7 | Fc epsilon RI signaling | 2.1 × 10−3 |
T helper cell differentiation (72) | 5.5 × 10−7 | Granulocyte adhesion and diapedesis | 3.6 × 10−6 |
Communication between innate and adaptive immune cells (112) | 6.6 × 10−5 | Agranulocute adhesion and diapedesis | 5.0 × 10−6 |
Primary immunodeficiency signaling (64) | 1.4 × 10−4 | Angiopoietin signaling | 1.2 × 10−3 |
CD28 signaling in T helper cells (126) | 8.1 × 10−4 | Caveolar-mediated endocytosis signaling | 2.0 × 10−3 |
Role of NFAT in regulation of the immune response (200) | 1.4 × 10−3 | eNOS signaling | 5.2 × 10−3 |
iCOS-iCOSL signaling in T helper cells (126) | 1.5 × 10−3 | Coagulation system | 5.6 × 10−3 |
Type I diabetes mellitus signaling (121) | 1.5 × 10−3 | Nitric oxide signaling in the cardiovascular system | 6.8 × 10−3 |
PKCθ signaling in T lymphocytes (144) | 1.6 × 10−3 | VEGF family ligand-receptor interactions | 1.0 × 10−2 |
AMR, antibody-mediated rejection; TCMR, T cell–mediated rejection.